Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevoflurane in COPD Exacerbation in ICU
NCT03460015Terminated
- Sponsor
- CHU Montpellier
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sevoflurane in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by CHU Montpellier. Primary endpoint: Evolution of airway resistance at 48 hours. Started Mar 2018; status: terminated.
02
Drugs
sevoflurane
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03460015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03460015.